Overview

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the investigators detect the VEGF-A,VEGF-C,VEGF-D,VEGFR-1,VEGFR-2,VEGFR-3 expression in tumor tissue by IHC and detect those protein expression level in plasma by ELISA. After at least 6 weeks treatment, the investigators detect again VEGF-A,VEGF-C,VEGF-D expression level in plasma by ELISA. The aim of the study is to identify whether those biomarkers could predict Bevacizumab efficacy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Bevacizumab
Calcium
Calcium, Dietary
Capecitabine
Leucovorin
Levoleucovorin
Oxaliplatin
Criteria
Inclusion Criteria:

- More than 18-years old,male or female

- Pathologically approved as unresectable/metastatic colorectal cancer

- KPS > 70% or ECOG 0-2

- HGB > 80 g/L, NEUT ≥ 1.5x109 /L, PLT ≥ 80x109 /L; CR < 1.5 x Upper normality,

- TB < 1.5 X Upper normality,AST or ALT < 2.5 x Upper normality.

- Signed consent

Exclusion Criteria:

- Other malignancies simultaneously except in situ cervix or nonmelanoma skin cancer

- Pregnancy or in lactation

- HGB < 80 g/L, NEUT < 1.5x109 /L, PLT < 80x109 /L; CR ≥ 1.5 x Upper normality, TB ≥ 2.5
X Upper normality,AST or ALT ≥2.5 x Upper normality,AKP ≥ 2.5 X Upper normality